#Diphtheria Forecast

[stevenwilliam12]

Global Diphtheria Market Insights, Epidemiology, and Future Outlook – 2032

Overview

Diphtheria, caused by the bacterium Corynebacterium diphtheriae, remains a critical public health concern despite the availability of vaccines. While the global burden has significantly reduced, outbreaks still occur, especially in low-resource settings. The diphtheria market spans preventive vaccines, diagnostic tools, and therapeutic interventions, with a projected rise in demand driven by enhanced healthcare infrastructure, public awareness, and immunization efforts. This report offers insights into the market trends, epidemiological patterns, and future outlook through 2032.

Market Insights

The diphtheria market is characterized by:

The dominance of DPT Vaccines: Diphtheria vaccines are often delivered as part of combined DPT (diphtheria, pertussis, and tetanus) immunization programs, which dominate the preventive segment.

Government and NGO Initiatives: Global health organizations, such as WHO, UNICEF, and GAVI, are actively involved in expanding immunization coverage to eradicate vaccine-preventable diseases.

Growing Investment in Diagnostics: Faster detection of diphtheria cases through point-of-care tests and lab-based diagnostics is gaining momentum.

Regional Disparities: While developed countries maintain low infection rates, emerging economies in Africa, Southeast Asia, and South Asia face challenges in vaccine distribution, leading to periodic outbreaks.

Epidemiology Trends

Diphtheria remains under control in high-income countries due to comprehensive immunization programs. However, sporadic outbreaks in under-vaccinated regions persist. The disease is endemic in parts of South Asia and Africa, where conflict, poverty, and weak healthcare systems hinder vaccine distribution. Occasional cases in Europe and North America reflect the risks posed by incomplete vaccination or migration from affected areas.

Future Outlook – 2032

The global diphtheria market is expected to grow steadily over the next decade, driven by:

Expanded Immunization Programs: Governments will focus on closing vaccination gaps through campaigns targeting high-risk populations.

Development of Next-Generation Vaccines: Combined vaccines with broader immunization coverage will drive innovation and improve compliance.

Advancements in Diagnostics and Surveillance: The need for rapid outbreak detection will boost investments in diagnostic technologies and digital disease monitoring tools.

Public-Private Partnerships: Collaboration between governments, pharmaceutical companies, and NGOs will ensure sustainable vaccine supply chains.

Conclusion

While diphtheria is largely preventable, maintaining high vaccination coverage is essential to avoid future outbreaks. The market outlook through 2032 reflects steady growth, propelled by advancements in vaccine technology, enhanced diagnostics, and focused immunization efforts in vulnerable regions. Strengthening healthcare systems and addressing vaccine hesitancy will be crucial for achieving sustained control over diphtheria worldwide.

Latest Reports Offered By DelveInsight:

Treatment-resistant Hypertension Market | Urticaria Or Hives Market | Alcohol Use Disorder Market | Androgen Insensitivity Syndrome Market | B-cell Chronic Lymphocytic Leukemia Market | Bevacizumab Biosimilar Insight | Blastic Plasmacytoid Dendritic Neoplasm Market | Bowen's Disease Market | Braf-mutant Metastatic Melanoma Market | Brain Hemorrhage Market | Bronchial Hyperreactivity Market | Cart-related Neurotoxicity Market | Contrast-induced Nephropathy Market | Endometrial Hyperplasia Market | Epstein Barr Virus Market | Glioma Market | Lamellar Icthyosis Market | Lower-limb Spasticity Market | Lymphatic Malformations Market | Microscopic Polyangiitis Market | Partial Onset Seizures Market | Platinum-resistant Relapsed Ovarian Cancer Market | Reactive Airways Disease Market | Severe Toxicities In Lymphoma Market | Singapore Healthcare Outlook Report | Status Epilepticus Market | Sternal Wound Infection Market

[health-views-updates]

2024-2032 Toxoid Vaccine Market Demand & Trends Analysis

The Toxoid Vaccine Market Revenue was valued at USD 6 billion in 2023 and is anticipated to reach USD 9 billion by 2032, registering a steady CAGR of 4.9% over the forecast period of 2024-2032. This growth is driven by increasing vaccination initiatives, rising awareness of immunization benefits, and advancements in vaccine development technologies globally.

Market Dynamics

The toxoid vaccine market is experiencing consistent growth due to a heightened focus on eradicating vaccine-preventable diseases such as tetanus and diphtheria. Governments and healthcare organizations worldwide are ramping up immunization programs, particularly in developing regions, to enhance public health outcomes.

Additionally, ongoing innovations in biotechnology and vaccine production techniques are contributing to the creation of safer, more effective toxoid vaccines. Increasing investments in research and development by pharmaceutical companies further boost market expansion, ensuring the availability of vaccines that address emerging health threats.

Regional Insights

North America holds a significant market share due to its robust healthcare infrastructure, high immunization coverage, and strong governmental support for vaccination initiatives. Meanwhile, the Asia-Pacific region is poised for rapid growth, driven by rising healthcare spending, growing population, and increased awareness of vaccination benefits.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/2676

Future Prospects

The global push for immunization, coupled with technological advancements in vaccine development, positions the toxoid vaccine market for sustained growth. The increasing demand for combination vaccines, which incorporate toxoid components, and the adoption of innovative vaccine delivery systems are expected to further propel market expansion.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[industrynewsupdates]

Blood Screening Market Key Companies, Growth and Forecast Report, 2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Blood Screening Market Report Highlights

• The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.

• North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.

• Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global sentinel node biopsy market size was estimated at USD 717.8 million in 2023 and is projected to grow at a CAGR of 7.0% from 2024 to 2030. 

• The global market for endoscopy operative devices reached a value of USD 10.34 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. 

Blood Screening Market Segmentation

Grand View Research has segmented the blood screening market by product, technology, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[tamanna31]

Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030

Blood Screening Market Size & Trends

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

Next Generation Sequencing

Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Sweden

Norway

Denmark

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[healthtech-katta]

Toxoid Vaccine Market to Reach USD 9 Billion by 2032

The global toxoid vaccine market, valued at approximately USD 6 billion in 2023, is projected to grow to USD 9 billion by 2032. This growth represents a compound annual growth rate (CAGR) of 4.9% during the forecast period from 2024 to 2032.

Key Drivers of Market Expansion

The rise in vaccination efforts and public health initiatives aimed at preventing diseases caused by bacterial toxins, such as diphtheria and tetanus, are significant factors driving the market's expansion. Enhanced awareness of the importance of immunization and increasing government support for vaccination programs are also contributing to this growth.

Technological Advancements and Innovation

Advancements in vaccine technology and research are playing a crucial role in the market's development. The introduction of more effective and safer toxoid vaccines, as well as improved manufacturing processes, are expected to drive the market forward. Additionally, ongoing research into new toxoid vaccines and combination vaccines is likely to provide further growth opportunities.

Regional Insights

North America currently leads the market due to well-established healthcare infrastructure and widespread vaccination programs. However, the Asia-Pacific region is anticipated to experience the highest growth rate, driven by increasing healthcare investments and rising awareness of vaccination benefits.

Future Outlook

The toxoid vaccine market is poised for steady growth over the coming years, supported by ongoing public health initiatives and technological innovations. As global efforts to combat vaccine-preventable diseases continue, the market is set to reach new heights by 2032.

[mitalipingale]

The Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is expected to reach US$ 8.67 billion by 2031 at a CAGR of 5.30%.

[tip-research24]

Vaccines And Vaccination Market Future Competitive Landscape, Trends, Opportunity and Forecast to 2030

Investors are expected to receive business-oriented market insights from The Insight Partners "Overview of Vaccines And Vaccination Market Share, Size, and 2030" | market study. This study incorporates forecasts for the future market in addition to operational variables. This research addresses a variety of possibilities accessible for Vaccines And Vaccination market participants in addition to drivers and obstacles. Valid facts included in this research have been framed using both primary and secondary research approaches.

Vaccines And Vaccination Market research delves deeply into many categories to provide a thorough perspective for both seasoned players and recent arrivals. Companies may guarantee they have a competitive edge by using this market research to have a better perspective and knowledge of the target audience. Before making significant investments, businesses must have a firm understanding of the market. It makes financial sense to allocate a modest portion of your company's expenditure to reliable market research.

Firms must take an open-minded attitude in light of the competitive landscape discussed in this research. Companies may utilize the objective insights provided by this market research to identify their strengths and limitations. Companies that can capitalize on the fresh ideas gained from competition analysis will have an edge in moving forward.

A market research report, which contains proof of market research and provides the best opportunity for businesses to fulfill their objectives, might serve as the cornerstone of your business strategy.

Key objectives of this research are:

Global Vaccines And Vaccination Market Insights- Market Share, Market Size, and CAGR

To Examine Drivers, Challenges, and Opportunities in Vaccines And Vaccination Market

To offer competitive strategic insights that help businesses ace the game

To offer an actionable market recommendation

To brief on the impact of COVID-19 and present an account of strategic responses businesses can plan.

To analyze the Vaccines And Vaccination market benchmarks.

COVID-19 Impact Analysis

Halting the operations temporarily, an epidemic of COVID-19 influenced on revenues of key Vaccines And Vaccination market players. This section presents details on the range of responses businesses have to pandemic impacts and assists companies in developing post-pandemic strategies. Moving further, this chapter offers insights into supply-demand parameters for businesses to rejoin the market.

Key companies in this Vaccines And Vaccination market are- Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZenecea plc, GlaxoSmithKline plc, Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, Novavax, Inc..

To Summarize the Offerings-

Market Forecast- Coverage- Market Size, Share, and CAGR | Forecast by 2030

Market Scope– Aim of the research, A glance at key chapters

Market Dynamics- Drivers, Challenges, Regional Trends, and Market Opportunities

Market Segmentation – Product, Application, End-use Industries, and Regional Growth Prospects.

Market Players – Key Market Players and Strategies

Recent Developments and Innovation in Vaccines And Vaccination Market

Covid-19 Analysis- Industry Landscape During and Post-Pandemic.

Regional Framework- Key Regional Markets, Growth Projections

Market Segmentation Based on Technology this market is categorized further into- :

Recombinant and Conjugate Vaccines

Live Attenuated Vaccines

Inactivated Vaccines

Toxoid Vaccines

Others

Based on Indication this market is categorized further into- :

Pneumococcal Disease

Influenza

Human Papilloma Virus

Meningococcal Disease

Rotavirus

Varicella

Diphtheria

Polio

Hepatitis

Other Indications

Based on End User this market is categorized further into- :

Pediatric

Adults

Travelers

Key regions Vaccines And Vaccination Market Research Report:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of Latin America)

The Middle East and Africa (Turkey, GCC, Rest of the Middle East and Africa)

Rest of the World

About Us: The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.

[nidarsanafwr]

Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Overview, Competitive Analysis and Forecast 2031

[stickyleadybloger]

https://dailybusinesspost.com/diphtheria-treatment-market-share-to-exhibit-a-rapid-growth/

Diphtheria treatment Market Share to Exhibit a Rapid Growth Forecast 2030

[health-views-updates]

The Future of Toxoid Vaccine Retail: A Look at Changing Consumer Behavior

The global Toxoid Vaccine Market Revenue, valued at US$ 6 billion in 2023, is on a growth trajectory, with estimates indicating it will reach US$ 9 billion by 2032. This increase reflects a compound annual growth rate (CAGR) of 4.9% during the forecast period from 2024 to 2032. The growth of this market is driven by the increasing prevalence of infectious diseases and the rising awareness of vaccination benefits among populations worldwide.

Toxoid vaccines are a critical component of public health strategies, as they protect against diseases caused by toxins produced by bacteria. These vaccines work by stimulating the immune system to produce antibodies against the toxins, providing effective immunity without causing the disease itself. Common examples of toxoid vaccines include those for tetanus and diphtheria, which have been instrumental in reducing morbidity and mortality associated with these infections.

Market Drivers

The rising incidence of infectious diseases, particularly in developing countries, is a significant driver of the Toxoid Vaccine Market. As healthcare systems improve and access to vaccines increases, more individuals are being vaccinated, leading to a greater demand for toxoid vaccines. Additionally, the World Health Organization's initiatives to promote vaccination programs globally are further contributing to market growth.

The increasing awareness of the importance of vaccination among populations is also a key factor fueling demand. Public health campaigns aimed at educating communities about the benefits of immunization are essential in reducing vaccine hesitancy and increasing vaccination rates. Furthermore, advancements in vaccine technology and formulation are leading to more effective and safer vaccines, which is likely to enhance their uptake.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/2686 

Emerging Trends

Expansion of Vaccination Programs: Many governments and health organizations are expanding their immunization programs to include more comprehensive vaccination schedules, which often incorporate toxoid vaccines. This expansion is expected to significantly increase the market size over the coming years.

Innovative Vaccine Development: The field of vaccine research is evolving, with ongoing efforts to develop novel toxoid vaccines that offer improved efficacy and safety profiles. These innovations are likely to attract investment and accelerate market growth.

Increasing Public-Private Partnerships: Collaborations between public health organizations and private companies are becoming more common, leading to enhanced vaccine distribution and availability. Such partnerships are crucial in ensuring that toxoid vaccines reach underserved populations.

Regional Insights

North America currently holds a significant share of the Toxoid Vaccine Market, driven by the presence of advanced healthcare infrastructure, high vaccination rates, and a strong emphasis on public health initiatives. The U.S. Centers for Disease Control and Prevention (CDC) plays a crucial role in promoting vaccine uptake and funding immunization programs.

The Asia-Pacific region is anticipated to witness the highest growth rate during the forecast period. Factors such as rapid urbanization, increasing healthcare expenditure, and government initiatives to improve vaccination coverage are propelling market expansion in countries like India and China. Additionally, rising awareness about the importance of immunization in controlling infectious diseases is further contributing to market growth in this region.

Key Players in the Market

The Toxoid Vaccine Market features several key players committed to advancing vaccine development and distribution. Major companies include GlaxoSmithKline, Merck & Co., Sanofi, Pfizer, and Novartis. These organizations are focusing on research and development to introduce innovative toxoid vaccines that meet the evolving needs of global health.

Conclusion

The global Toxoid Vaccine Market is set for steady growth, driven by the rising prevalence of infectious diseases, increased awareness of vaccination benefits, and advancements in vaccine technology. As public health initiatives continue to promote immunization, the demand for toxoid vaccines is expected to grow, creating significant opportunities for market players in the coming years.

[industrynewsupdates]

Blood Screening Market Analysis, Opportunities And Forecast Report 2024-2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

• The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

• Abbott

• Danaher Corporation (Beckman Coulter)

• Becton Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Hoffman-La Roche Ltd.

• Grifols, S.A.

• Ortho-Clinical Diagnostics, Inc.

• Siemens Healthcare GmbH

• Thermo Fisher Scientific, Inc.

• SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.